On 13 September 2026, IonOpticks announced the IonOpticks Aurora Series 5, calling it the most significant robustness upgrade in the platform’s history. The release pairs a new CoreJet integrated emitter architecture with a redesigned nanoZero union. Both target one goal: making nanoflow chromatography survive the grind of routine, high-throughput proteomics.
The headline claim is specific. In extended testing on a Thermo Vanquish Neo coupled to an Orbitrap Astral Zoom, Series 5 sustained over 10,000 unique protein identifications across more than 1,000 injections. The method ran at 120 samples per day with an 8-minute gradient.
Backpressure did not climb beyond 1,400 runs. Coefficients of variation stayed below one per cent for median protein and peptide identifications. No spray dropouts occurred on either the Thermo or Bruker platform.
Those numbers matter because proteomics is shifting from bespoke experiments to industrial-scale processing. But they are company-run numbers. No peer-reviewed publication supports them yet. The sample type behind the 10,000-protein figure is undisclosed. Pricing — the variable that decides whether “lower cost per sample” is real — appears nowhere in the release.
There is also a structural tension the release does not acknowledge. IonOpticks Aurora Series 5 is a third-party consumable for instruments whose manufacturer, Thermo Fisher, sells competing columns. The battle for routine proteomics is increasingly about whose consumable sits in front of the mass spectrometer.
Why Now: The Timing Logic
Proteomics is going industrial
The field has moved from single experiments toward population-scale campaigns. A 2025 preprint for the PCA-N workflow reported 36,000 plasma samples measured continuously over 311 days. China’s π-HuB project runs a data factory of 15 LC-MS/MS instruments, generating over 40,000 datasets at up to 360 samples per day. Sample preparation methods now scale beyond 10,000 samples per day in 384-well formats.
Instruments have kept pace. Thermo’s Orbitrap Astral line enables 100-samples-per-day throughput in 24/7 operation. Bruker’s timsTOF series drives similar high-throughput DIA workflows. The weak link is increasingly the front end: the chromatography column. A column that clogs at injection 300, or a spray that fails mid-cohort, wastes instrument time that costs more per hour than the column itself.
That is the gap Aurora Series 5 targets. Robustness is not a marketing nicety in this market. It is the difference between a cohort study that finishes and one that restarts.
A 16-month product cycle under private equity
IonOpticks is no longer a slow-moving spinout. The firm was incubated at Melbourne’s WEHI (Walter and Eliza Hall Institute), founded in 2017, and acquired by Nordic private equity firm Adelis Equity Partners in September 2024. Since the Adelis deal, the company has launched Generation 4 Aurora in May 2025 and now Series 5 in September 2026. That is a full generation refresh in 16 months.
The company is also scaling commercially. IonOpticks ships to 35 countries and counts 16 of the top 20 global pharmaceutical companies as customers. Headcount has grown roughly 39 per cent year-on-year to about 61 people across seven countries. A Bruker OEM partnership (2022) and a SCIEX co-marketing agreement (2024) extend its reach across instrument ecosystems.
Riding the Astral Zoom cycle
The robustness testing was run on Thermo’s newest Orbitrap Astral Zoom, paired with the Vanquish Neo. This is deliberate co-positioning. Researchers buying Astral-class instruments are the ones attempting high-throughput deep proteomics. IonOpticks wants its column to be the default consumable in front of that detector. Testing on Bruker’s nanoElute 2 coupled to a timsTOF HT extends the same message to the other major instrument camp.
The Competitive Picture
The real battle: third-party consumables versus the instrument maker
Thermo Fisher does not just make the Vanquish Neo. It sells its own column line for it. EASY-Spray PepMap Neo columns integrate the emitter and temperature control in one unit, rated to 1,500 bar. The µPAC Neo Plus pillar-array columns promise column-to-column reproducibility with lower backpressure. The newer OptiSpray cartridge system adds exchangeable emitters, letting users replace a worn tip without replacing the whole column.
IonOpticks’ pitch against this lineup is performance-per-dollar. The Gen 4 launch quoted CEO Xavier Perronnet framing it directly: upgrade the column, not the mass spec. Aurora columns have historically outperformed in-house packed columns and Thermo’s stock offerings on peptide coverage in third-party testimonials. The Bruker Focus Series OEM deal means Bruker itself resells Aurora-derived columns.
But Thermo has structural advantages. Its columns ship with its instruments and its service engineers support them. The integrated source ecosystem — EASY-Spray, OptiSpray — is designed to lock in compatibility.
IonOpticks wins only when researchers actively choose a third-party column over the bundled default. That makes independent performance evidence, not press releases, the decisive sales instrument.
Where IonOpticks Aurora Series 5 positions within that fight
The CoreJet redesign attacks a specific weakness: dead volume at the column-emitter junction. Concealed unions between column and emitter degrade peak shape and reduce analyte discovery. CoreJet integrates the emitter fully into the analytical column, guaranteeing true-zero dead volume after the column.
Thermo’s EASY-Spray has offered an integrated column-emitter design for years. The OptiSpray system takes a different route with modular, swappable emitters. CoreJet’s differentiation is architectural: no replaceable parts, no unions at all, one fused flow path from packing to tip. Whether that beats a swappable-emitter design on total cost of ownership depends on column price and failure modes. The release quantifies neither.
What the Data Shows
The claims, and what sits behind them
The 10,000-protein figure echoes what deep-proteome studies achieve on Astral-class instruments with HeLa digest. But the release does not name the sample type. At 120 samples per day with an 8-minute gradient, the claim implies roughly 9,000 protein IDs per run sustained across 1,000 runs.
Published Astral work reports around 9,000 proteins from HeLa at 100 SPD over 10-plus days. The claim is plausible in kind but unverified in detail. HeLa digest is a far friendlier matrix than undepleted plasma, where 700 to 850 proteins at 100 SPD is the published benchmark.
The reproducibility claim — CVs below one per cent for median protein and peptide identifications — is strong. If independently confirmed, it would matter more than raw depth. Cohort studies die from quantitative drift, not from missing proteins.
The no-backpressure-climb-beyond-1,400-runs claim addresses the most common nano column failure mode: clogging that raises pressure until the run aborts. Combined with the NanoShield C18 trap for dirty-sample protection, the story is coherent. It is also entirely self-reported. The release specifies no external testing partners or planned peer-reviewed publication.
What the market context says independently
The proteomics market is growing at 10 to 13 per cent annually. Estimates for 2026 range from roughly $33 billion to $47 billion depending on the research house. Reagents and consumables dominate revenue share at around 70 per cent. That is why a consumables vendor is fighting this hard for column mindshare.
Mass spectrometry holds roughly a third of the technology mix. High-throughput MS platforms are a named growth driver in every major market report.
The customer economics are straightforward. A core facility running 120 samples per day processes roughly 40,000 samples a year. If IonOpticks Aurora Series 5 columns genuinely survive 1,400 injections where competitors survive hundreds, column replacement frequency drops several-fold. Instrument downtime drops with it. That arithmetic — not protein counts — is what a facility manager will model before switching.
What’s New vs. What’s Repackaged
Genuinely new
CoreJet’s emitter architecture. The complete redesign of the integrated pulled emitter eliminates concealed unions and delivers true-zero post-column dead volume. This is a real engineering change to the product’s core component, not a rebrand of the existing design.
The redesigned nanoZero union. A more reliable voltage connection for stable electrospray ionisation addresses a practical, frequent pain point in daily setup and long runs.
The 120 SPD robustness envelope. Sustaining nanoflow performance at 120 samples per day across 1,000-plus injections, if verified, extends the published robustness frontier. That frontier has mostly been demonstrated at 100 SPD.
Repackaged
Robustness as the headline. Generation 4, launched May 2025, already claimed enhanced robustness, longevity, spray stability, and reproducibility. Series 5 escalates the same narrative with better numbers. The direction is consistent. The framing as a historic step-change is marketing calibration.
Integrated emitters as a category. Aurora columns have always integrated the emitter. Thermo’s EASY-Spray has sold the concept for a decade. CoreJet is new for Aurora, not new for the market.
Reproducibility emphasis. Column-to-column and batch-to-batch consistency have been IonOpticks talking points since the WEHI days. The founding team famously refined column success rates from 20 per cent to 99 per cent.
Unclear
Pricing and cost per sample. The release claims lower cost per sample without any figures. Column price, expected lifetime, and price-performance against OptiSpray’s replaceable-emitter model are all undisclosed.
The test matrix. The sample type behind the 10,000-protein claim is not stated. HeLa digest and undepleted plasma produce wildly different protein counts. Buyers cannot judge the claim without knowing which matrix was run.
Independent validation. No external laboratory, peer-reviewed paper, or instrument-vendor co-signed testing is cited. The Bruker Focus OEM history shows IonOpticks can win vendor validation. None appears here.
Cross-generation reproducibility. Labs mid-way through multi-year cohorts on Series 4 need to know whether Series 5 reproduces Series 4 quantification closely enough to switch mid-study. The release says limited Series 4 stock remains during transition. It says nothing about equivalence.
The Question That Wasn’t Answered
What does it cost, and against what alternative?
Every claim in the release funnels toward lower cost per sample, yet no price appears. For a facility manager, the comparison is three-way: IonOpticks Aurora Series 5 at an unknown price and 1,400-run lifetime; Thermo’s OptiSpray with replaceable emitters; and in-house packed columns at low material cost but high labour. Without column pricing, the central economic claim cannot be evaluated.
Can you switch cohorts from Series 4 to Series 5?
Population-scale studies run for months or years. A column generation change mid-cohort risks batch effects between old and new columns. The release addresses continuity of supply but not continuity of data. Until IonOpticks publishes cross-generation comparison data, risk-averse labs will finish their cohorts on Series 4. That may be exactly why limited stock remains.
Is CoreJet defensible, or fast-followable?
Integrated-emitter architectures are well-trodden patent territory across the industry. If CoreJet’s specific design is patented, IonOpticks holds a window. If not, Thermo’s column division can iterate toward the same zero-dead-volume endpoint within its own ecosystem. The release is silent on IP status.
What happens when the instrument makers bundle harder?
Thermo’s OptiSpray push — cartridge consumables, automated emitter positioning, on-instrument integration — shows the instrument maker building toward the same ease-and-robustness territory IonOpticks claims. Third-party consumables vendors survive on measurable performance advantage. The press release does not explain what happens when that advantage is matched by a bundled competitor.
What This Means for You
For proteomics core facility managers
Model the economics before the protein counts. If your facility runs high-throughput DIA cohorts, request evaluation columns and run your own injection series to failure on your real sample matrix. Plasma, not HeLa, if plasma is what you process.
Ask IonOpticks for Series 4 versus Series 5 cross-comparison data before switching mid-cohort. The robustness claims are promising. They are also unverified outside the company’s own lab.
For pharma and clinical proteomics leads
IonOpticks Aurora Series 5 is worth benchmarking if instrument uptime and column replacement frequency are your binding constraints. The 120 SPD claim aligns with where Astral-class and timsTOF workflows are heading. But the decision should rest on a head-to-head against your current column using your cohort’s sample type and your quantification requirements. It should not rest on the release’s HeLa-scale depth figures.
For life-science tools investors and market watchers
IonOpticks is a PE-backed consumables pure-play riding the single largest revenue pool in proteomics. Reagents and consumables account for roughly 70 per cent of a $40-billion-class market. The 16-month generation cycle under Adelis shows product velocity. The strategic risk is concentration: the company depends on staying the preferred third-party column for instruments whose maker wants that business for itself. Watch for independent validation publications, the Series 4-to-5 migration rate, and any Thermo response in the OptiSpray line.
Editor’s Note
This article draws on the IonOpticks press release dated 13 September 2026, distributed via PR Newswire, supplemented by independent web research. Company-claimed information includes all performance figures: the 10,000-plus unique protein identifications, 1,000-plus injection sustained testing, 8-minute 120 SPD method, no backpressure climb beyond 1,400 runs, CVs below one per cent, no spray dropouts across both platforms, the CoreJet and nanoZero design descriptions, and the NanoShield compatibility claim. Independently verified information includes IonOpticks’ WEHI origin and 2017 founding, the Adelis Equity Partners acquisition of September 2024, the Bruker OEM partnership of 2022, the SCIEX co-marketing agreement of 2024, the Generation 4 launch of May 2025 and its stated claims, headcount and customer base figures from IonOpticks and WEHI sources, Thermo’s competing column portfolio (EASY-Spray, µPAC Neo Plus, OptiSpray), published high-throughput proteomics benchmarks including 100 SPD Orbitrap Astral studies, the PCA-N 36,000-sample campaign, the π-HuB data factory, and proteomics market size estimates from Grand View Research, Mordor Intelligence, and Fortune Business Insights. IonOpticks did not disclose pricing, the test sample matrix, CoreJet patent status, or Series 4-to-5 cross-generation equivalence data in the release. We could not independently verify any Series 5 performance claim.